-
Tadalafil, Eli Lillyâs blockbuster drug for erectile dysfunction, has now been approved to treat signs and symptoms of benign prostatic hyperplasia. Tadalafil is the first drug of its class to be approved for this indication.
-
-
From a large cohort of women followed prospectively and with an adjunct meta-analysis of existing evaluable studies, a clearly demonstrated, nearly universal (i.e., across tumor types) incremental increase in cancer incidence was observed with advancing height.
-
A newly developed instrument to measure brief physical activity counseling in primary care demonstrates that physicians need to do a better job.
-
Recent retrospective studies in Europe have created concern because of an observed increased risk of cancer (hazard ratio = 1.55) in users of insulin glargine (GLAR) compared to nonusers.
-
The authors conclude that patients with coronary stents undergoing an invasive procedure are at high risk of perioperative cardiovascular and bleeding complications, and that these are associated with a high mortality.
-
In this issue: Medication poisonings in children; rosuvastatin vs atorvastatin for atherosclerosis; saw palmetto for prostate symptoms; using atypical antipsychotics for off-label indications in adults; and FDA actions.
-
Mr. Evans is Executive Editor of the Infectious Disease Group at AHC Media LLC, in Atlanta, GA; he writes for Hospital Infection Control & Prevention and the HICprevent blog at http://hicprevent.blogs.reliasmedia.com/. This article originally appeared in the October issue of Hospital Infection Control & Prevention.
-
A 40-year-old Gambian male with end-stage renal disease secondary to focal segmental glomerulosclerosis (FSGS) was evaluated for a living unrelated kidney transplant.
-
In this issue: New recommendations for HPV vaccine; guidelines for treatment of essential tremor; updates on smoking cessation drugs; and FDA actions.
